The Effects of Pancreatic Enzyme Supplementation in Critically Ill Patients on Enteral Feeding
NCT ID: NCT05112328
Last Updated: 2021-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
170 participants
INTERVENTIONAL
2021-07-07
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
Exocrine Pacancreatic enzyme(Norzyme Capsule 40000 capsules) after meals 3 times a day
Exocrine Pancreatic Enzyme
Pancreatic enzyme supplementation for critically ill patients on enteral nutrition
Control
Placebo after meals 3 times a day
Placebo
Placebo of Pancreatic enzyme for critically ill patients on enteral nutrition
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exocrine Pancreatic Enzyme
Pancreatic enzyme supplementation for critically ill patients on enteral nutrition
Placebo
Placebo of Pancreatic enzyme for critically ill patients on enteral nutrition
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hospitalized in the surgical/medical intensive care unit of the Seoul National University Hospital
* Enteral nutrition
* Patients who consented to this study
* Patients with risk factors for pancreatic exocrine dysfunction
* Shock (Norepinephrine)
* Sepsis (3 rd definition of sepsis)
* Diabetes
* Cardiac arrest
* hyperlactatemia serum lactate \> 2 mmol/L)
* Mechanical ventilation
* Continuous renal replacement therapy
Exclusion Criteria
* unresectable pancreatic cancer
* History of pancreatectomy
* Underlying diseases in which the effect of Exocrine pancreatic enzyme administration is difficult to show
* Inflammatory bowel disease
* Short bowel syndrome
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Seung-Young Oh
Clinical Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, Jongno-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Seoul National University Hospital
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-185-1153
Identifier Type: -
Identifier Source: org_study_id